|New Threads Only:|
|New Threads & Replies:|
Forum List » Business News and Headlines|
SEC Filings, Earing Reports, Press Releases
Misonix Announces New HIFU Distribution Agreement for Italy
Posted by: gurufocus (IP Logged)
Date: January 5, 2009 04:02PM
Press Release: Misonix Announces New HIFU Distribution Agreement for Italy Misonix Inc. designs develops manufactures and markets medical scientific and industrial ultrasonic equipment laboratory safety equipment and air pollution control products. Misonix's ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Misonix acquired worldwide rights to use the Focus technology in kidney liver and breast treatment. Addressing a combined market estimated to be in excess of $four billion annually Misonix's proprietary ultrasonic medical devices are used for wound debridement cosmetic surgery neurosurgery laparoscopic surgery and other surgical and medical applications. MISONIX Inc. has a market cap of $4.7 million; its shares were traded at around $0.86 with and P/S ratio of 0.1.
Alliance Lithomobile is well known in
The Sonablate is a state of the art HIFU instrument used for the trans-rectal ablation of tumors of the prostate gland. Characteristics of HIFU, when used for this purpose, are clinical outcomes similar to other treatment modalities, but with low instances of urinary incontinence and sexual impotence.
"Misonix is pleased to partner with Lithomobile to provide prostate HIFU treatment for prostate cancer to hospitals throughout
Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contact: Cameron Associates, Inc. 212-245-4577 Kevin@cameronassoc.com
Stocks Discussed: MSON,